RT Book, Section
A1 Friedman, Lawrence S.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193152539
T1 Cirrhosis
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193152539
RD 2024/04/19
AB Key  Clinical  Updates  in  CirrhosisIn  patients  with  clinically  significant  portal  hypertension,  carvedilol,  a  nonselective  beta  receptor  antagonist  with  alpha-1  blocking  activity,  appears  to  reduce  the  frequency  of  decompensating  events,  although  it  may  lead  to  hypotension  particularly  in  patients  with  decompensated  cirrhosis.Tandon  P  et  al.  Clin  Gastroenterol  Hepatol.  [PMID:  33221550]Vancomycin  should  be  added  in  patients  with  prior  bacterial  peritonitis  or  a  positive  surveillance  swab  for  methicillin-resistant  Staphylococcus  aureus.  Daptomycin  should  be  added  in  patients  with  a  positive  surveillance  swab  for  vancomycin-resistant  enterococcus.  Meropenem  can  be  used  in  patients  with  current  or  recent  exposure  to  piperacillin-tazobactam.Biggins  SW  et  al.  Hepatology.  [PMID:  33942342]